01093.HK
CSPC Pharmaceutical Group Limited
HKSE · Healthcare · Drug Manufacturers - General · CN
HKD 7.87
−2.18%Aug 18, 2026, 10:38 UTC
Shanghai Second Intermediate People's Court will conduct a second judicial auction of 2.5 million shares of Shiyao Jingfeng held by shareholder Ye Xiangwu from September 3 to 6, 2026, after the first auction failed.
Source:Aug 10, 2026, 10:58 UTC
Shijiazhuang Pharmaceutical Group's monkeypox mRNA vaccine SYS6037 injection, developed in cooperation with the Institute of Microbiology of the Chinese Academy of Sciences, received US FDA approval to conduct clinical trials.
Source:Jul 30, 2026, 23:56 UTC
CSPC Pharmaceutical Group's wholly-owned subsidiary CSPC Zhongqi plans to enter into a second foreign exchange forward contract with Industrial and Commercial Bank of China to buy USD 90 million for RMB 612 million.
Source:Jul 28, 2026, 02:02 UTC
CSPC Pharmaceutical Group's marketing application for injectable sirolimus (albumin-bound) was accepted by the National Medical Products Administration and granted priority review.
Source:Jul 28, 2026, 01:38 UTC
Shiyao Group expects its interim comprehensive profit to be between 5.9 billion and 6.2 billion RMB.
Source:Jul 27, 2026, 12:59 UTC
CSPC Pharmaceutical Group announced that its Class 1 innovative drug Amoxetine Hydrochloride Enteric-coated Tablets (HA1406) met the primary endpoint in a Phase III clinical trial for depression.
Source:Jul 27, 2026, 02:09 UTC
CSPC Pharmaceutical Group's self-developed second-generation long-acting antipsychotic injection, Paliperidone Palmitate Injection, received marketing approval from China's National Medical Products Administration for the treatment of acute and maintenance phases of schizophrenia.
Source:Jul 24, 2026, 02:05 UTC
CSPC Pharmaceutical Group's new drug application for Enwei Trastuzumab Injection has been accepted by China's National Medical Products Administration.
Source:Jul 23, 2026, 02:09 UTC
Takeda's neuroscience drug Ozeyue (Opreton) received approval from China's National Medical Products Administration for treating narcolepsy type 1 in patients aged 16 and above, making China the first market globally to approve the drug.
Jul 21, 2026, 19:36 UTC
Several Chinese public funds, including E Fund, China Asset Management, Fullgoal Fund, and China Universal Fund, increased their holdings in Hong Kong-listed biotech stocks, triggering the 5% disclosure threshold for Baioct-B, 3SBio, CSPC Pharmaceutical Group, Kelun-Biotech, and H&H International Holdings.
← PreviousPage 2